Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396591 · ClinicalTrials.gov registry record · Phase 2
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
A Phase 2 study of Ovarian Neoplasms, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 3
- Study locations
NCT00396591 is a Phase 2 study of Ovarian Neoplasms that has completed, run by Sanofi. The registered enrollment target is 16 participants, below the 367-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00396591, a Phase 2 study of Ovarian Neoplasms, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic malignant ascites. The secondary objectives were to further assess efficacy and safety of Aflibercept treatment, and the exploratory objectives were to assess pharmacokinetics, immunogenicity and health-related quality of life.
Conditions Studied
Interventions
- DRUG Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Study Locations (3)
Other
- Sanofi-Aventis Administrative Office - Milan
- Sanofi-Aventis Administrative Office - Bromma
New Jersey
- Sanofi-Aventis Administrative Office - Bridgewater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00396591
The ClinicalTrials.gov registry entry for NCT00396591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 367-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) is the first listed.
NCT00396591 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Other, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00396591 about?
NCT00396591 is a clinical study titled "AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites". The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic malignant ascites. The secondary objectives were to further assess efficacy...
What is the current status of trial NCT00396591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-10. Estimated completion is 2008-11.
What conditions does trial NCT00396591 study?
This clinical trial studies the following conditions: Ovarian Neoplasms.
What interventions are being tested in trial NCT00396591?
The interventions under investigation include: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) (DRUG).
Who is sponsoring clinical trial NCT00396591?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00396591 being conducted?
This trial has 3 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.